Beta Drugs H1 FY27 Results: Revenue up 29% to ₹263 Cr

Key takeaway from the H1 FY27 print

Beta Drugs Limited reported a strong first half for FY27, even as it flagged global market uncertainty in its communication around the results. Consolidated revenue from operations rose 29.2% year-on-year to ₹263.04 crore in H1 FY27, compared with ₹203.6 crore in H1 FY26. Profitability improved alongside growth, with consolidated EBITDA at ₹61 crore versus ₹47 crore in the previous year period. EBITDA margin expanded to about 23.2% in H1 FY27. Profit after tax (excluding minority interest) increased to ₹34.3 crore from ₹23.9 crore.

What the company reported for H1 FY27

The company’s H1 FY27 numbers point to both scale-up and steady operating discipline. EBITDA margin was reported at 23.18% in H1 FY27, broadly in line with the 23.2% level highlighted in the presentation and commentary. The same disclosures also put PAT margin at 13.1% for H1 FY27. Gross margin moved up to 56.2% in H1 FY27 from 51.4% in H1 FY26, as per the investor presentation. Alongside the headline performance, the company highlighted strength across key business segments including Branded Oncology and CMO.

Segment performance and mix signals

Beta Drugs’ H1 FY27 segment revenue mix, as stated in the presentation, shows CMO as the largest contributor in the period. Segment revenues for H1 FY27 were Branded Products at ₹71 crore, Nivian at ₹31 crore, Exports at ₹43 crore, CMO at ₹95 crore, and Others at ₹23 crore. The “Others” bucket includes Derma and API sales for H1 FY27.

Within branded businesses, the company highlighted Nivian brand sales of ₹31 crore, with 75% year-on-year growth reported for the brand. Management also stated a medium-term target of 20%-22% growth in branded oncology, and more than 50% growth in Nivian during FY27. These targets were presented alongside the company’s broader expectation of a stronger second half compared with H1 FY27.

Operational factors that influenced the half

Beta Drugs said the Branded Oncology segment recorded 17% growth during H1 FY27. At the same time, it flagged that production shutdowns linked to debottlenecking and capacity expansion at the Adley Formulations plant affected sales. The disclosure is important because it frames part of the H1 trajectory as being shaped by planned operational work rather than demand softness.

In the API business, the presentation stated that the business grew by about 30%. It also indicated that new capacity is expected to go onstream in Q4 FY27, alongside investments toward capacity expansion and backward integration.

Export pipeline: filings, registrations and approvals

Export execution was supported by a steady regulatory pipeline. During H1 FY27, Beta Drugs filed 76 new product dossiers across selected export markets, taking total registrations to 415. The same material noted more than 800 products at different stages of development or planned for filing over the next two years. Separately, the investor presentation also showed a registration pipeline of 872 across regions.

For the half-year, export formulations sales were stated at ₹43 crore. The company also reported that 35 approvals were received during H1 FY27.

Board meeting, results approval and disclosures

Beta Drugs announced a board meeting to discuss operational and financial performance for Q2 and H1 FY27. A conference call was scheduled for Thursday, 22 October 2026. The company also disclosed that the board approved Q2/H1 FY27 standalone and consolidated results on 22 October 2026, and auditors issued an unmodified review.

A separate note around the Q2 FY27 investor presentation stated “Beta Drugs Q2 Results 2026 (FY27): Revenue ₹31 Cr, EBITDA margin 23.2%.” The same context also indicated the company had not published an earnings-call transcript for the quarter, and that figures referenced were from the investor presentation rather than management guidance.

Guidance for FY27: revenue and margin band

Management expects Beta Drugs to close FY27 with revenue of ₹535 crore or more, with EBITDA margins in the 23%-24% range. The company’s H1 FY27 consolidated revenue was ₹263.04 crore, and EBITDA margin stood at 23.18%. The stated FY27 outlook therefore implies a stronger second half compared with the first half performance.

Capital structure and balance sheet highlights shared

The investor presentation included a set of balance sheet and capital structure indicators. It stated that equity share capital increased from ₹181 crore in H1 FY25 to ₹475 crore in H1 FY27. Borrowings were stated at ₹49 crore in H1 FY27.

For H1 FY27, the same disclosure listed total liabilities at ₹656 crore and total assets at ₹656 crore. Fixed assets net of depreciation were stated at ₹229 crore, and cash and cash equivalents at ₹104 crore.

Quick table: financial and operating snapshot

Market impact and what investors tracked

Outside the H1 update, the dataset also included Q1 FY27 numbers that indicated continued momentum going into the year. Q1 FY27 revenue from operations was stated at ₹125.55 crore (₹1,255 million), up 25.2% year-on-year from ₹100.2 crore (₹1,002 million) in Q1 FY26. Net profit in Q1 FY27 was stated at ₹15.80 crore, with operating margin at 21.80% and return on equity at 53.00%.

A separate point-in-time note dated 27 July 2026 stated that Q1 FY27 results were formally disclosed on 20 July 2026, and that the stock had rallied 72.9% over the prior three months. The same note also referenced the company’s 66.09% acquisition of Nivian Lifesciences, and cited an acquisition figure of ₹69.4 crore.

Why the H1 FY27 update matters

The H1 FY27 print combines three elements investors typically focus on in pharma and specialty formulations: growth, margins, and execution on capacity and filings. Revenue growth of 29.2% came with stable-to-improving operating margins, while gross margin expansion to 56.2% suggests mix and cost dynamics moved favourably in the half. At the same time, the company acknowledged that debottlenecking and capacity expansion at Adley Formulations affected sales, linking part of the growth profile to operational timing.

The FY27 expectation of ₹535 crore or more revenue, with 23%-24% EBITDA margins, sets a clear benchmark for the second half. The filings and registrations data also provides a measurable track for export business readiness, with 76 dossiers filed in H1 FY27 and 35 approvals received during the period.

Conclusion

Beta Drugs’ H1 FY27 performance showed higher revenue, higher EBITDA, and stronger profit year-on-year, while maintaining EBITDA margin around 23.2%. The company’s disclosures also pointed to operational changes at Adley Formulations and continued investment into capacity and backward integration, with new API capacity expected in Q4 FY27. Next milestones for investors include tracking how the second half shapes up against the FY27 revenue expectation of ₹535 crore or more, and updates from the scheduled conference call and subsequent filings.